Læknablaðið - 15.12.2007, Qupperneq 20

FRÆÐIGREINAR
METÝLFENÍDAT
kostnað stuttverkandi lyfjaforms. Samanborið
við Evrópulönd er notkun metýlfenídats á íslandi
mikil. Aldursdreifing og kynhlutfall lyfjanotkunar
er svipað og víðast annars staðar og kemur einnig
heim og saman við dreifingu ADHD hjá börnum.
Miðað við tíðnitölur ADHD er ekki hægt að álykta
að um ofnotkun lyfjanna sé að ræða hér á landi.
Hins vegar er nauðsynlegt að vandlega sé staðið
að greiningu ADHD hjá börnum og að önnur
meðferðar- og stuðningsúrræði séu reynd fyrir og
samhliða lyfjagjöf. Mikilvægt er að stuðla að skyn-
samlegri lyfjanotkun og að þeir hljóti viðeigandi
meðferð sem á þurfa að halda.
Höfundar leggja til frekari að gerður verði frek-
ari samanburður á geðlyfjanotkun og meðferð-
arúrræðum barna milli landa í framtíðinni. Einnig
er þarft að kanna algengi og dreifingu lyfjanotk-
unar við ADHD hjá fullorðnum á íslandi. Loks
hlýtur það að teljast verðugt verkefni að kostn-
aðargreina meðferðarúrræði ADHD, til dæmis
hvort aukin notkun dýrari lyfjaforma sé þjóðhags-
lega hagkvæm.
Þakkir
Þakkir fá Hrefna Þorbjarnardóttir, ritari og
Kristinn Jónsson, kerfisfræðingur.
Heimildir
1. Costello EJ, Mustillo S, Erkanli A, Keeler G, Angold A.
Prevalence and development of psychiatric disorders in
childhood and adolescence. Arch Gen Psychiatry 2003; 60:
837-44.
2. Cuffe SP, Moore CG, McKeown RE. Prevalence and correlates
of ADHD symptoms in the national health interview survey.
J Atten Disord 2005; 9: 392-401.
3. Woodruff TJ, Axelrad DA, Kyle AD, Nweke O, Miller GG,
Hurley BJ.Pediatrics. Trends in environmentally related
childhood illnesses 2004; 113:1133-40.
4. Faraone SV, Sergeant J, Gillberg C, Biederman J. The
worldwide prevalence of ADHD: is it an American condition?
World Psychiatry 2003; 2:104-13.
5. Barkley RA. Primary Symtoms, Diagnostic Criteria,
Prevalence, and Gender Differences. In: Barkley RA, ed.
Attention Deficit/Hyperactivity disorder. A handbook for
diagnosis and treatment. Third edition. New York: Guilford
2005: 76-121.
6. Bradley C. The behavior of children receiving benzedrine.
Am J Psychiatry 1937; 94: 577-85.
7. Barkley RA. History. In: Barkley RA, ed. Attention Deficit/
Hyperactivity disorder. A handbook for diagnosis and
treatment. Third edition. New York: Guilford 2005:3-52.
8. Connor DF. Stimulants. In: Barkley RA, ed. Attention Deficit/
Hyperactivity disorder. A handbook for diagnosis and
treatment. Third edition. New York: Guilford 2005: 608- 47 .
9. Scheffler RM, Hinshaw SP, Modrek S, Levine P. The global
market for ADHD medications. Health Aff (Millwood) 2007;
26:450-57.
10. Olfson M, Marcus SC, Weissman MM, Jensen P. National
Trends in the Use of Psychotropic Medications by Children. J
Am Acad Child Adolesc Psychiatry 2002; 41:514 -21.
11. Zuvekas SH, Vitiello B, Norquist GS. Recent Trends in
Stimulant Medication Use Among U.S. Children. Am J
Psychiatry 2006; 163: 579-85.
12. National Institute for Health and Clinical Excellence,
National Health Service. NICE implementation uptake
report: attention deficit hyperactivity disorder, 16.04.2007:
www.nice.org.uk
13. The Norwegian Institute of Public Health. Over 11 000 bam
og unge behandles med ADHD-medisiner. Reseptbasert
legemiddelregister, Grossistbasert legemiddelstatistikk.
13.02.2006, 01.03.2007: www.fhi.no
14. The Danish Medicines Agency. Lægemiddelstatistikregisteret:
www.medstat.dk
15. Lyfjadeild TR - lyfjaskírteini vinnureglur. Metýlfenídat. 1.
júm' 2007 www.tr.is
16. Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS.
Trends in medication treatment for ADHD. J Atten Disord
2007; 10: 335-42.
17. Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson
P, Buitelaar J, et. al.Long-acting medications for the
hyperkynetic disorders: A systematic review and European
treatment guidelines. Eur Child Adolesc Psychiatry 2006; 15:
476-95.
18. Baldursson G, Magnusson P, Guðmundsson OO. Greiningar
og meðferðarúrræði 102 bama og unglinga sem komu
til bama- og unglingageðdeildar Landsptítalans vegna
ofvirknieinkenna frá 1. júní 1998 til 31. maí 1999. Læknablaðið
2000; 86: 337-42.
19. Faraone SV, Biederman J, Weber W, Russell RL. Psychiatric,
neuropsychological, and psychosocial features of DSM-IV
subtypes of attention-deficit/hyperactivity disorder: results
from a clinically referred sample. J Am Acad Child Adolesc
Psychiatry 1998; 37:185-93.
20. Jónsdóttir S. ADHD and its relationship to comorbidity and
gender. Doktorsritgerð varin við læknadeild Rijksuniversiteit
Groningen, Hollandi 27. september 2006.
21. Biederman J, Mick E, Faraone SV, Braaten E, Doyle A,
Spencer T, et. al. Influence Of Gender On Attention Deficit
Hyperactivity Disorder In Children Referred To A Psychiatric
Clinic. Am J Psychiatry 2002; 159: 36-42.
22. American Academy of Pediatrics. Clinical practice guideline:
diagnosis and evaluation of the child with attention-deficit/
hyperactivity disorder. Pediatrics 2000; 105:1158-70.
23. Cox ER, Motheral BR, Henderson RR, Mager D. Geographic
variation in the prevalence of stimulant medication use
among children 5 to 14 years old: results from a commercially
insured US sample. Pediatrics 2003; 111:237-43.
24. Milton A, Eberhard D. Child and adolescent psychiatry in
Iceland: Report from a brief study tour. September 2006.
25. MTA Cooperative group. A 14-month randomized clinical
trial of treatment strategies for attention-deficit/hyperactivity
disorder. Multimodal treatment study of children with
ADHD. Arch Gen Psychiatry 1999; 56:1097-9.
26. Conners CK, Epstein JN, March JS, Angold, A, Wells K C,
Klaric J, et al. Multimodal treatment of ADHD in the MTA:
An altemative outcome analysis. J Am Acad Child Adolesc
Psychiatry 2001; 40:159-67.
27. MTA Cooperative Group. National Institute of Mental Health
Multimodal Treatment Study of ADHD follow up: 24-month
outcomes of treatment strategies for attention-deficit/
hyperactivity disorder. Pediatrics 2004; 113: 754-61.
28. Barkley RA, McMurray MB, Edelbrock CS, Robbins K.
Side effects of methylphenidate in children with attention
deficit hyperactivity disorder: a systemic, placebo-controlled
evaluation. Pediatrics 1990; 86:184-92.
29. Greenhill LL, Halperin JM, Abikoff H. Stimulant medications.
Am Acad Child Adolesc Psychiatry 1999; 38:503-12.
30. Santosh PJ, Taylor E. Stimulant drugs. Eur Child Adolesc
Psychiatry 2000; 9:127-43.
31. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley
JS. Is methylphenidate like cocanine? Studies on their
pharmacokinetics and distribution in the human brain. Arch
Gen Psychiatry 1995; 52: 456-63.
32. Wilens TE, Faraone SV, Biederman J, Gunawardene, S. Does
stimulant therapy of attention deficit/hyperactivity disorder
beget later substance abuse? A meta-analytic review of the
literature. Pediatrics 2003; 111:179-85.
832 LÆKNAblaðið 2007/93